BridgeBio Pharma, Inc.
NASDAQ:BBIOBiotechnology
+$0.75 today
- Market cap
- $15.20B
- Beta
- 0.97
- P/E (TTM)
- -18.1
- EPS (TTM)
- -$3.73
Volume 3.55M
Average 2.49M
BBIO Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
BridgeBio Pharma, Inc.NASDAQ: BBIO
Gross Profit · Q2 FY2026 · quarter ended Jun 2026
Gross profit grows, but more slowly than its trailing trend
Q2 FY2026 gross profit of $228.63M rose 113.8% year over year, behind the +193.4% change in trailing-twelve-month gross profit. Sequentially, it rose 24.2% from the prior quarter. Over 3 fiscal years it compounded at +85.5% a year.
Context
- Gross profit amounted to 94.4% of revenue in FY2025, down 3.9 pp from a year earlier.
- Gross profit increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +113.8% toward the trailing-twelve-month pace of +193.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 473.81M USD
- Year-over-year change
- +117.3%
- 4-year CAGR
- +63.3%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 473.81M | +117.3% |
| FY2024 | 2024-12-31 | 218.02M | +3079.6% |
| FY2023 | 2023-12-31 | 6.86M | -90.8% |
| FY2022 | 2022-12-31 | 74.21M | +11.4% |
| FY2021 | 2021-12-31 | 66.6M | — |
Gross Profit vs competitors
How BBIO compares with its peers on the latest reported figures
- Peers report in different currencies, so gross profit is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +193.4% is the 2nd highest of 10, against a peer median of +11.3%.
- Gross profit amounts to 93.3% of revenue for BBIO, versus a peer median of 82.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $821.17B USD | +32536.1% | +16.0% | 79.9% | |
| LTM Jun 2026 | $3.83B USD | +86.0% | +51.8% | 79.7% | |
| LTM Sep 2026 | €1.09B EUR | +95.1% | +147.0% | 90.6% | |
| LTM Sep 2026 | $942.72M USD | -1.3% | +17.4% | 98.2% | |
| LTM Jun 2026 | $828.57M USD | -51.6% | +36.4% | 82.1% | |
| LTM Jun 2026 | $665.62M USD | +193.4% | +85.5% | 93.3% | |
| LTM Mar 2026 | $559.44M USD | +11.3% | +19.0% | 83.6% | |
| LTM Sep 2026 | $394.98M USD | -7.2% | +66.0% | 60.7% | |
| LTM Mar 2026 | $18.41M USD | -89.0% | — | 92.0% | |
| LTM Jun 2026 | -$2.2M USD | — | — | 61.0% | |
| LTM Sep 2026 | -$46.95M USD | +53.0% | — | 8236.0% | |
| Peer median (excluding BBIO) | — | +11.3% | +36.4% | 82.9% | |
Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 69.72M | 77.65M | 9.3M | 221.9M | 502.08M |
| Cost of Revenue | 3.11M | 3.43M | 2.45M | 3.88M | 28.27M |
| Gross Profit | 66.6M | 74.21M | 6.86M | 218.02M | 473.81M |
| Gross Margin | 95.5% | 95.6% | 73.7% | 98.3% | 94.4% |
| Research & Development | 451.02M | 399.46M | 455.71M | 506.46M | 477.54M |
| Selling, General & Admin | 192.21M | 143.19M | 150.59M | 288.93M | 555.14M |
| Operating Expenses | 643.23M | 586.42M | 614.23M | 811M | 1.04B |
| Depreciation & Amortization | 5.84M | 6.77M | 6.49M | 6.08M | 5.43M |
| EBITDA | (533.83M) | (397.44M) | (565.47M) | (436.83M) | (676.45M) |
| EBITDA Margin | -765.7% | -511.9% | -6078.3% | -196.9% | -134.7% |
| Operating Income | (576.63M) | (512.2M) | (607.37M) | (592.97M) | (569.09M) |
| Operating Margin | -827.1% | -659.6% | -6528.8% | -267.2% | -113.3% |
| Interest Income | 1.13M | 7.54M | 18.04M | 17.25M | 19.85M |
| Interest Expense | 46.78M | 80.44M | 81.29M | 99.29M | 53.1M |
| Other Income / Expenses | (9.82M) | 27.55M | (45.88M) | 50.78M | (165.9M) |
| Income Before Tax | (586.45M) | (484.65M) | (653.25M) | (542.19M) | (734.99M) |
| Pre-Tax Margin | -841.2% | -624.2% | -7021.9% | -244.3% | -146.4% |
| Income Tax Expense | 0 | 0 | 0 | 1.15M | 555K |
| Net Income | (562.54M) | (481.18M) | (643.2M) | (535.76M) | (729.31M) |
| Net Margin | -806.9% | -619.7% | -6913.9% | -241.4% | -145.3% |
| EPS (Basic) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| EPS (Diluted) | (3.90) | (3.35) | (3.95) | (2.88) | (3.79) |
| Weighted Avg Shares | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
| Weighted Avg Shares (Diluted) | 144.36M | 147.47M | 162.79M | 186.08M | 197.24M |
BridgeBio Pharma, Inc.
NASDAQ:BBIO
Intrinsic Alpha fair value
Locked
Current Price
$78.01
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.